Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2021-01-01
2023-02-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background: One of the most common problems encountered in transplant patients is incompatibility with immunosuppressive drugs, one of the most important reasons for graft rejection.
Design: A randomized controlled trial was conducted from January to October 2021 and conducted in accordance with the Consolidated Standards of Reporting Trials 2010 guidelines.
Methods: This randomized controlled trial included a total of 100 patients receiving a kidney transplant, 50 in the intervention group and 50 in the control group. Patients in the intervention group were sent text message reminders four times a day during the 6th to 9th months after transplantation. Control patients received no such intervention. Tacrolimus concentrations in the bloodstream were monitored for all participants through measurements taken at months 7,8, and 9. Data collection tools included Sociodemographic and Descriptive Characteristics Form and Immunosuppressive Medication Adherence Scale.
Research hypotheses H1- Sending text message reminders improves immunosuppressive medication adherence in kidney transplant recipients.
H2- Utilization of text messages as reminders has a significant influence on tacrolimus blood profiles in kidney transplant recipients.
H3- There is a correlation between the scores from the Immunosuppressive Medication Adherence Scale and mean tacrolimus plasma levels in kidney transplant recipients.
H4- There is a correlation between the sociodemographic and descriptive characteristics of kidney transplant recipients and their mean scores from the Immunosuppressive Medication Adherence Scale.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Measuring and Improving Medication Adherence in Kidney Transplant Patients
NCT02639949
Adherence Enhancement for Renal Transplant Patients
NCT01859273
Video Education and Behaviour Contract to Optimize Adherence in Renal Transplants
NCT03540121
Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3
NCT04288271
Survey of Adherence to Immunosuppression and Other Medications in Kidney Transplant Patients
NCT00433134
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
reminder text message
At the baseline of the study, the Sociodemographic and Descriptive Characteristics Form and IMAS were administered to patients in the intervention groups as a pretest. Short text messages to remind the use of immunosuppressive medication and educational text messages were sent to patients in the intervention group four times a day, every day for three months. The intervention group also received educational text messages three days a week, in addition to such text message reminders.
The text message contents prepared for the intervention group were sent automatically to patients at specified times via the purchased program. At the end of the study, intervention groups of participants completing the 9-month follow-up were administered the IMAS questionnaire as a posttest.
reminder text message
The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
no intervention
At the baseline of the study, the Sociodemographic and Descriptive Characteristics Form and IMAS were administered to patients in the control groups as a pretest. The control group did not receive any such intervention. At the end of the study, control groups of participants completing the 9-month follow-up were administered the IMAS questionnaire as a posttest.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
reminder text message
The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being a recipient of a kidney transplant for the first time
* Being a kidney transplant recipient at post-transplant month 6 with scheduled follow-up until month 9
* Ongoing immunosuppressive drug therapy
* Absence of any disability that hinders communication
* No diagnosis of psychological and mental problems
* Being an active cell phone user
* Ability to read and write
* Voluntary participation in the research.
Exclusion Criteria
* History of combined or dual organ transplantation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Akdeniz University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kübra Erdal
Nurse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akdeniz University
Antalya, Konyaalti, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KAEK-315
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.